Procedures for establishing and maintaining consistent air-kerma strength standards for low-energy, photon-emitting brachytherapy sources: recommendations of the Calibration Laboratory Accreditation Subcommittee of the American Association of Physicists in Medicine.

Low dose rate brachytherapy is being used extensively for the treatment of prostate cancer. As of September 2003, there are a total of thirteen 125I and seven 103Pd sources that have calibrations from the National Institute of Standards and Technology (NIST) and the Accredited Dosimetry Calibration Laboratories (ADCLs) of the American Association of Physicists in Medicine (AAPM). The dosimetry standards for these sources are traceable to the NIST wide-angle free-air chamber. Procedures have been developed by the AAPM Calibration Laboratory Accreditation Subcommittee to standardize quality assurance and calibration, and to maintain the dosimetric traceability of these sources to ensure accurate clinical dosimetry. A description of these procedures is provided to the clinical users for traceability purposes as well as to provide guidance to the manufacturers of brachytherapy sources and ADCLs with regard to these procedures.

[1]  R Nath,et al.  Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee. Ad Hoc Subcommittee of the Radiation Therapy Committee. , 1998, Medical physics.

[2]  J. Williamson,et al.  Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 interstitial sources: dosimetry and calibration changes: recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. , 1999, Medical physics.

[3]  J F Williamson,et al.  Code of practice for brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group No. 56. American Association of Physicists in Medicine. , 1997, Medical physics.

[4]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[5]  K. Wallner,et al.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[6]  A. D'Amico,et al.  Prostate brachytherapy , 1999, Cancer.

[7]  W. Cavanagh,et al.  1–125 Versus Pd‐103 for Low‐Risk Prostate Cancer: Morbidity Outcomes from a Prospective Randomized Multicenter Trial , 2002, Cancer journal.

[8]  J. Palta,et al.  Comprehensive QA for radiation oncology: report of AAPM Radiation Therapy Committee Task Group 40. , 1994, Medical physics.

[9]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[10]  W Cavanagh,et al.  Palladium-103 brachytherapy for prostate carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[11]  Blasko,et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[12]  J F Williamson,et al.  Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. , 2000, Medical physics.

[13]  J. Blasko,et al.  Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. , 2002, Seminars in radiation oncology.